Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.55 |
| ▸ | ROS1 | P08922 | 1/20 | 0.55 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1707411 | 0.99 | EGFR (0.55) | EGFRLRRK2METALKROS1 | |
| SCHEMBL1707172 | 0.93 | EGFR (0.58) | EGFRLRRK2METALKROS1 | |
| SCHEMBL1708506 | 0.92 | EGFR (0.59) | EGFRLRRK2METALKROS1 | |
| SCHEMBL1707112 | 0.90 | ALK (0.64) | EGFRLRRK2METALKROS1 | |
| SCHEMBL1707551 | 0.89 | EGFR (0.54) | EGFRLRRK2METALKROS1 | |
| SCHEMBL1037690 | 0.89 | EGFR (0.61) | EGFRLRRK2METALKROS1 | |
| SCHEMBL1707028 | 0.89 | EGFR (0.59) | EGFRLRRK2METALKROS1 | |
| SCHEMBL1707026 | 0.89 | EGFR (0.57) | EGFRLRRK2METALKROS1 | |
| SCHEMBL1707456 | 0.88 | EGFR (0.51) | EGFRLRRK2METALKROS1 | |
| SCHEMBL9911242 | 0.88 | EGFR (0.55) | EGFRLRRK2METALKROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| WO-2010142766-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | ZAP70, LCK, DPY30 | EGFR 3420/4885LRRK2 3072/4885MET 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.